Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS 2 articles
July 26, 2004
- NEW PRODUCT
July 26, 2004
- Semi-annual Business Results
July 26, 2004
- GSK Developing Multiple Kinase Inhibitors: GSK Symposium 2004
July 26, 2004
- WORLD NEWS IN BRIEF
July 26, 2004
- PRESS SEMINAR
July 26, 2004
- 2 WG to Discuss Problems with Drug Distribution: Ryukaikon
July 26, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 26, 2004
- Import of Zometa Inj 4 mg Approved
July 26, 2004
- MEDICAL DEVICE NEWS IN BRIEF
July 26, 2004
- Supplementary Notification on Amended PAL Issued
July 26, 2004
- DIAGNOSTIC NEWS IN BRIEF
July 26, 2004
- Mr Asonuma Reviews 1st Year of New PAL Enforcement
July 26, 2004
- Licensing Out POTTELIGENT Technology: Mr Matsuda of Kyowa Hakko
July 26, 2004
- REGULATORY NEWS IN BRIEF
July 26, 2004
- Interpretation on Reimbursement of Off-label Use Issued by HIB
July 26, 2004
- Over 50% of Directors of Private Hospitals Support Management by Stock Companies
July 26, 2004
- FY2004 Is Critical for Restoring Good Financial Results: Mr Miyatake of Dainippon
July 19, 2004
- Takara Bio Supplies RetroNectin to NCI of the US for Gene Therapy Trial
July 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
July 19, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…